Emory Transplant Center, Emory University, Atlanta, GA, USA.
Am J Transplant. 2012 Nov;12(11):3143-51. doi: 10.1111/j.1600-6143.2012.04241.x. Epub 2012 Sep 4.
CD154 is an immunostimulatory ligand for CD40 that markedly influences alloimmunity. Its presence in platelets suggests that its release and subsequent immune effects are driven by trauma and thus could be relevant following organ transplantation. However, the release of platelet derived CD154 and its consequences have not been investigated in a clinical transplant setting. To better characterize the relationship between platelet activation and CD154 release, we investigated CD154 release by platelets obtained from normal individuals, and patients with two genetic defects that influence platelet granule development. Using these unique patient populations and immune-electron microscopy, we confirmed that CD154 was an alpha granule and not a cell surface protein, and thereafter optimized the methods for its in vivo measurement in humans. We then investigated plasma CD154 levels in kidney and liver transplant recipients and found no evidence that CD154 levels fluctuated systemically as a result of kidney or liver transplant procedures. Paradoxically, we found that kidney transplant patients had significantly lower systemic CD154 levels during episodes of rejection. These data suggest that the immune effects of CD154 are likely mediated through local and not systemic mechanisms, and discourage the use of CD154 as a peripheral biomarker in organ transplantation.
CD154 是一种免疫刺激性配体 CD40,对同种异体免疫有显著影响。其在血小板中的存在表明,其释放及其随后的免疫效应是由创伤驱动的,因此在器官移植后可能相关。然而,在临床移植环境中,尚未研究血小板衍生的 CD154 的释放及其后果。为了更好地表征血小板激活与 CD154 释放之间的关系,我们研究了来自正常个体和两种影响血小板颗粒发育的遗传缺陷患者的血小板中 CD154 的释放。使用这些独特的患者群体和免疫电子显微镜,我们证实 CD154 是一种α颗粒,而不是细胞表面蛋白,此后优化了其在人类体内测量的方法。然后,我们研究了肾和肝移植受者的血浆 CD154 水平,并未发现 CD154 水平因肾或肝移植手术而系统性波动的证据。矛盾的是,我们发现肾移植患者在排斥反应期间全身 CD154 水平显著降低。这些数据表明,CD154 的免疫效应可能通过局部而不是全身机制介导,并劝阻将 CD154 用作器官移植中的外周生物标志物。